Iovance Biotherapeutics
在场
是其中之一......
Iovance Biotherapeutics 是一家在股票代码 IOVA (US) 下上市的公司。
涉及Iovance Biotherapeutics的并购和融资。
- Iovance Biotherapeutics 刚刚宣布为 150 筹款数百万美元。 (公布2023七月13号).
高管
查看带有其 20 名主要高管的组织结构图
Iovance Biotherapeutics 搜索最多的简介
- Frederick Vogt, Interim Chief Executive Officer, President and Gen...
- Wayne Rothbaum, Director
- Athena Countouriotis, Director
创建提醒
跟踪 Iovance Biotherapeutics 的高管变动
生物技术
Iovance Biotherapeutics 拥有 2,282 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Endeavor BioMedicines 刚刚宣布为 132 筹款数百万美元。 (公布2024四月25号).
- Metsera 刚刚宣布为 290 筹款数百万美元。 (公布2024四月23号).
- Histogen has filed for bankruptcy protection (公布2024四月19号).
生物技术 行业的其他推荐联系人
消息
Iovance Biotherapeutics 的最新新闻稿
- Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022 | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors | Iovance Biotherapeutics, Inc.
- Press Releases | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics to Present at Upcoming Conferences | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting | Iovance Biotherapeutics, Inc.
- View more press releases Close
通过电子邮件
